Dupilumab-induced erythema nodosum
Danielle E. Mustin, Emily Cole, Travis W. Blalock, Merin Kuruvilla, Benjamin K. Stoff, Ron J. Feldman
Abstract
Dupilumab is a fully human monoclonal antibody that functions as an interleukin (IL) 4α receptor antagonist, inhibiting the activity of both IL-4 and IL-13, drivers of T helper 2 mediated inflammation. Although injection-site reactions are the most reported side effect, there have been several reported cases of adverse dermatologic reactions, including facial and neck erythema.1,2 We present a case of a patient with severe eosinophilic asthma and chronic sinusitis with nasal polyps in whom drug-induced erythema nodosum (EN) developed after 8 weeks of dupilumab therapy.
Topics & Concepts
MedicineDupilumabDermatologyErythema nodosumErythemaSinusitisAdverse effectMonoclonal antibodyImmunologyAtopic dermatitisPathologyAntibodyInternal medicineDiseaseAsthma and respiratory diseasesRespiratory and Cough-Related Research